بسم الله الرحمن الرحيم



السيد الأستاذ الدكتور/ رئيس قسم الميكروبيولوجي الطبيه والمناعة

برجاء التكرم بالموافقة على مجمل أبحاثي العلمية لتقديمها للجنة العلمية الدائمة (الأساتذة والأساتذة المساعدين) للترقية لدرجة \$quot،أستاذ مساعد\$quot؛

th Research &

LncRNAs, MALAT1 and Inc-DC as potential biomarkers for multiple sclerosis diagnosis

By

Olfat Gamil Shaker. Biochemistry Department, Faculty of Medicine, Cairo .\\
.University

Rania Hosny Mahmoud. Biochemistry Department, Faculty of Medicine. ₹

.Fayoum University

'Omima Awis Abd-Aleem. Biochemistry Department, Faculty of Medicine."

.Fayoum University

د Enas Gomaa Ibrahim. Microbiology Department, Faculty of Medicine. ٤

.Fayoum University

Abd-Alrahman Ahmed Mohamed. Microbiology Department, Faculty of.º

.Medicine, Fayoum University

Othman Mohamed Zaki. Clinical Pathology Department, Faculty of. 7

.Medicine, Fayoum University

Noha Abd-Elghafar. Clinical Pathology Department, Faculty of Medicine.

.Fayoum University

'Tarek Ibrahim Ahmed. Internal Medicine Department, Faculty of Medicine.

.Fayoum University

Nada Fathy Hemeda. Genetic Department, Faculty of Agriculture, Fayoum. 9

.University

Nagla Atef. Physiology Department, Faculty of Medicine, Zagazeg. 1 •

.University

Dina Fathy Mansour. Neurology Department, Faculty of Medicine, Minya . \ \

.University

.Type of research: Join international

Published on: Bioscience Reports, 2019

Abstract

Long non-coding RNAs (IncRNAs) play an important role in gene regulation and show greatertissue specificity and complexity of biological functions. There is on-going research in theircontribution in autoimmune diseases like multiple sclerosis (MS). Our study aimed at theevaluation of serum levels of IncRNAs, MALAT1 and Inc-DC in MS patients and the investigation of the association between these IncRNAs and the disease activity. Serum from45 MS patients and 45 healthy controls was -separated. MALAT1 and Inc-DC expression levels were assayed by qRT PCR. MALAT1 and Inc-DC were significantly increased in MS patients P=0.004 and P=0.006, respectively) in comparison with controls. There) was a significantincrease in expression of MALAT1 in secondary '(progressive MS (SPMS) subgroup compared with controls (P&It;0.0001 however, significant elevation of Inc-DC was demonstrated in relapsing remitting MS (RRMS) subtype (P=0.003) compared with normal .controls

A positive association between the expression levels of MALAT1 and $. Inc\text{-DC (r = 0.513, P \< 0.0001) in MS patients was detected} \\ \text{-Moreover, positive correlation was observed between MALAT1 and Inc} \\ \text{-DC in RRMS (r = 0.569, P = 0.001)}. Serum levels of MALAT1 and Inc} \\ \text{DC may serve as potential novel molecular biomarkers for MS diagnosis}} \\ \text{.and may provide a new direction for its treatment} \\$